Megan Gibbs

THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

Angela C. Doran, R. Scott Obach, Bill J. Smith et al. · Drug Metabolism and Disposition · 2004 · 440 citations

Inhibition of Cytochrome P-450 3A (CYP3A) in Human Intestinal and Liver Microsomes: Comparison of Ki Values and Impact of CYP3A5 Expression

Megan Gibbs, Kenneth E. Thummel, Danny D. Shen et al. · Drug Metabolism and Disposition · 1999 · 244 citations

Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies

Jennifer Dong, David H. Salinger, Christopher J. Endres et al. · Clinical Pharmacokinetics · 2011 · 153 citations

Translational Medicine, Medicine, Biostatistics +6

Single‐Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers

Hélène M. Faessel, Bill J. Smith, Megan Gibbs et al. · The Journal of Clinical Pharmacology · 2006 · 104 citations

Multiple‐Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers

Hélène M. Faessel, Megan Gibbs, David J. Clark et al. · The Journal of Clinical Pharmacology · 2006 · 93 citations

Dose Level, Tobacco Control, Healthy Adult Smokers +12